Prestige Brand Holdings Stock News

Prestige Consumer Healthcare In with ticker code (PBH) now have 4 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 72 and 63 calculating the average target price we see 68. Given that the stocks previous close was at 58.99 this is indicating there is a potential upside of 15.3%. The 50 day MA is 59.18 and the 200 moving average now moves to 52.94. The market capitalisation for the company is $2,957m. Find out more information at: https://www.prestigebrands.com [stock_market_widget type="chart" symbol="PBH" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody''s analgesic powders, Boudreaux''s Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye allergies/redness relief, Compound W wart removals, Debrox ear wax removals, DenTek for PEG oral care, and Dramamine for motion sickness relief.

Wall Street analysts expect Prestige Consumer Healthcare Inc. (NYSE:PBH) to post earnings of $0.89 per share for the current quarter, Zacks reports. Three analysts have made estimates for Prestige Consumer Healthcares earnings. The highest EPS estimate is $0.89 and the lowest is $0.88. Prestige Consumer Healthcare reported earnings of $0.81 per share during the same []

The average age of first pregnancy has increased dramatically worldwide in recent decades, due to a decrease in first births among teenagers and an increase in first births among women over 30 years of age. Increased support for a pregnancy

Head lice are little, wingless, blood-sucking insects that infest in hair. They feed off the blood from your scalp that causes irritation or typically results in huge pimples on the pinnacle. The male lice is far larger in size compared to

Brokerages forecast that Prestige Consumer Healthcare Inc. (NYSE:PBH) will announce sales of $259.99 million for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Prestige Consumer Healthcares earnings, with estimates ranging from $259.50 million to $260.48 million. Prestige Consumer Healthcare reported sales of $238.79 million in the same quarter last year, []

Foundry Partners LLC purchased a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 169,605 shares of the companys stock, valued at approximately $9,517,000. Several other hedge funds also recently modified []

Wells Fargo & Company MN cut its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,680,288 shares of the companys stock after selling 15,270 shares during the quarter. Wells Fargo & Company []

Stratagem Market Insights announced that it’s published an exclusive report namely Antihistamines Travel Sickness Drugs Market by Size, Share, Growth, Manufacturers, Regions, Type, and Application, Forecast to 2028 in its research database with report summary, table of content, research

UBS Asset Management Americas Inc. raised its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 5.4% in the second quarter, Holdings Channel reports. The fund owned 67,467 shares of the companys stock after acquiring an additional 3,448 shares during the period. UBS Asset Management Americas Inc.s holdings in Prestige Consumer Healthcare were worth $3,515,000 at []

Brokerages forecast that Prestige Consumer Healthcare Inc. (NYSE:PBH) will post sales of $259.99 million for the current quarter, Zacks reports. Three analysts have provided estimates for Prestige Consumer Healthcares earnings. The highest sales estimate is $260.48 million and the lowest is $259.50 million. Prestige Consumer Healthcare posted sales of $238.79 million in the same quarter []

Prestige Consumer Healthcare Inc. (PBH) CEO Ron Lombardi on Q2 2022 Results - Earnings Call Transcript

Prestige Consumer's (PBH) Q2 results reflect gains from solid demand and continued recovery in certain categories. Encouragingly, it raises the fiscal 2022 guidance.

Prestige Consumer's (PBH) performance in the fiscal second quarter is likely to have gained from strong brand offerings, especially in healthcare, as well as growing e-commerce sales.

TARRYTOWN, N.Y., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2022 second quarter earnings release on Thursday, November

LCUT vs. PBH: Which Stock Is the Better Value Option?